

REMARKS/ARGUMENTS

After entry of this paper, claims 4-10, 12, 13, 15 and 24 are pending. Claim 1 was amended to place the application in condition for allowance and to clarify the invention. Support for this amendment is found on page 11, line 32. No new matter is added by this amendment.

Information Disclosure Statement Objection

The Examiner asserted that the Toyama document cited in the Information Disclosure Statement filed May 6, 2004 fails to comply with the provisions of 37 CFR §§ 1.97 and 1.98 and MPEP § 609 since it does not include a translation.

Applicants respectfully request reconsideration and withdrawal of this rejection for the following reason.

With respect, Applicants assert that MPEP § 609 provides that:

"Translations are not required to be filed unless they have been reduced to writing..." and

"If no translation is submitted, the examiner will consider the information in view of the concise explanation and insofar as it is understood on its face, e.g...English language abstracts...in the same manner that non-English language information in Office search files is considered by examiners in conducting searches." ¹

In the present application and as required under 37 CFR § 1.97(3)(i), Applicants provided on pages 2-3 of the Information Disclosure Statement (IDS) dated May 1, 2003 a concise explanation of the information contained in the Toyama document to the extent possible. Further,

¹ Col. 1, Para. 2, Page 600-129 of the MPEP

Applicants provided a copy of an English language Abstract of Toyama as document CG.

For the Examiner's information, the US Patent and Trademark Office indicated receipt of this IDS, and the copies of the documents cited therein, on May 6, 2003. Applicants have enclosed a copy of the stamped postcard as Exhibit A.

Further, upon reviewing the secure section of PAIR for this application, Applicants noted that an electronic copy of document CG was available. Specifically, document CG was identified under the heading "NPL Documents" on May 6, 2003 and noted as being 6 pages in length. In an effort to assist the Examiner in locating this document, Applicants have provided the first page of document CG as obtained from PAIR as Exhibit B. Applicants have also noted the location of this document on page 3 on the printout from PAIR for this application, which printout is enclosed herewith as Exhibit C.

In view thereof, Applicants respectfully request that the Toyama document be considered during examination of this application.

Reconsideration of this objection is requested.

35 USC § 112, First Paragraph Rejection

Claims 4-10, 12, 13, 15, and 24 are rejected under 35 USC § 112, first paragraph.

*The Examiner asserted that Applicants are not considered to be in possession of the genus of oligos that hybridize to **any** ACAT.*

Applicants respectfully request reconsideration and withdrawal of this rejection for the following reason.

In an effort to place the application in condition for allowance, Applicants specified that the antisense oligonucleotide sequences hybridize to the ACAT sequence of SEQ ID NO: 3 and are 100% complementary to a sequence within the nucleic acid sequence spanning nucleotide 14 to 1741 of SEQ ID NO: 3.

Reconsideration of this rejection is requested.

35 USC § 103 Rejection

Claims 4-10, 12, 13, 15, and 24 are rejected under 35 USC § 103(a) over US Patent No. 5,968,749 (Chang I et al.) or US Patent No. 5,484,727 (Chang II et al.) in view of US Patent No. 5,801,154 (Baracchini et al.) and Drug Discovery Today, 1999, 4(12):562-567 (Taylor).

Applicants respectfully request reconsideration and withdrawal of this rejection for the following reason.

With respect, Applicants maintain that the combination of Chang I and/or II, Baracchini and Taylor does not make a *prima facie* obviousness rejection of the pending claims.

Applicants wish to clarify their prior remarks about Taylor, which is a peer-reviewed article. Taylor's allegations about the ease and straightforward manner of determining target sites on a gene that permit one to identify suitable antisense oligonucleotides of a high degree of inhibition are not *a priori* true for any target. Taylor **alleges** without evidence that screening 3-6 oligomers per target is sufficient to find one that inhibits any gene with 66-95% efficiency. In rebuttal, the

Rule 132 Declaration filed by Applicants demonstrated that such an allegation is not universally true about oligonucleotides to any known sequence selected as an antisense target. The evidence in Applicant's Declaration is provided to show that for the two targets identified in the Declaration, one skilled in the art may screen many oligonucleotides without success in identifying a target site permitting a high level of inhibition. One skilled in the art could not expect, *prior to screening*, that an antisense oligonucleotide with high inhibitory action against **any** selected target can be identified simply because antisense methodologies are known in general and a gene sequence of the proposed target is published.

Further, the combination of Chang I and II, Baracchini and Taylor at best provides only an indication that it is obvious **to try** to make an antisense sequence capable of inhibiting ACAT.

Chang I and II do not disclose methods of using the antisense compounds discussed therein to inhibit **endogenous** ACAT expression in cells or tissues, such as is required by Applicants. Chang I and II also do not provide any specific antisense compositions or lead one to the specific sequence of nucleotide 14-1371 of the ACAT of SEQ ID NO: 3 referred to by Applicants' amended claims.

Baracchini does not contain any disclosure that suggests or refers to the protein ACAT, does not provide any suggestion that permits one to identify or suggest specific ACAT sequences of SEQ ID NO: 3 as target sequences for binding by a specific antisense sequence or provide any desired minimal level of inhibitory activity of ACAT

antisense compounds, and does not teach or suggest any sequence for antisense compounds that bind to ACAT.

An obviousness rejection based on a combination of Baracchini's generic disclosures about antisense sequences in general (and specifically with regard to MRP) and Chang I or II's disclosure of a method of testing an inhibitory agent to ACAT, which agent may be **an unidentified, unspecific** antisense sequence, coupled with Taylor's misleading conclusion of the expectedness and simplicity of active site identification on the target genes is defective. An obviousness rejection cannot be made by combining documents to make the bald suggestion that it is "obvious to try" to make antisense compounds to target ACAT.

Applicants are not claiming any and all antisense sequences that target any ACAT. Rather, Applicants' claims recite only sequences between 8 and 50 nucleobases in length that specifically hybridize within nucleotides 14-1741 of SEQ ID NO: 3 and which inhibit expression of the resulting enzyme **by at least 12%** in a cell **endogenously** expressing ACAT-1.

Taking each reference as a whole, the combination of Baracchini, Chang I or II, and Taylor does not provide any *suggestion* of Applicants' specifically-claimed antisense sequences or methods. This combination does not provide the suggestion that the subject matter of Applicants' claims is expected or even likely to be useful for inhibiting gene expression.

Reconsideration of this rejection is requested.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicants

By Mary E. Bak
Mary E. Bak
Registration No. 31,215
Spring House Corporate Center
Box 457
Spring House, PA 19477
Telephone: (215) 540-9200
Telefacsimile: (215) 540-5818




Exhibit A

Serial No.: 09/920,394 Doc. No.: ISPH-0589 Atty/Sec: MEB/tup Date: 5/1/03
Inventor : Crooke et al. Client: ISIS
Title: ANTISENSE MODULATION OF ACYL COENZYME A CHOLESTEROL
ACYLTRANSFERASE-1 EXPRESSION

The following has been received in the US Patent and Trademark Office on the date stamped hereon:

- 1 pp. RCE Transmittal Letter
 - 5 pp. Second Information Disclosure Statement with PTO-1449 and 8 references
 - 8 pp. Response: OA dated December 4, 2002
 - 2 pp. Petition for Extension of Time
 - 1 pp. Fee Transmittal Letter
- Check #19895 for \$580.00

Respectfully,
HOWSON AND HOWSON



BEST AVAILABLE COPY

02/22746
(16)

15PH-694

2

DERWENT-ACC-NO: 1994-238652
DERWENT-WEEK: 199429
COPYRIGHT 1999 DERWENT INFORMATION LTD

TITLE: ACAT inhibitor to reduce hypercholesterolaemia - comprising pyrimidine and/or purine base and/or nucleoside or nucleotide contg. the base(s), used to treat arteriosclerosis

PATENT-ASSIGNEE: TOYAMA CHEM CO LTD[TOYA]

PRIORITY-DATA: 1992JP-0350738 (December 4, 1992)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|---------------|---------------|----------|-------|-------------|
| JP 06172186 A | June 21, 1994 | N/A | 004 | A61K 031/70 |

APPLICATION-DATA:

| PUB-NO | APPL-DESCRIPTOR | APPL-NO | APPL-DATE |
|-------------|-----------------|----------------|------------------|
| JP06172186A | N/A | 1992JP-0350738 | December 4, 1992 |

INT-CL (IPC): A23L001/30; A61K031/70; C07H019/06; C07H019/16;
C12N009/99

ABSTRACTED-PUB-NO: JP06172186A

BASIC-ABSTRACT: Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor (I) contains one or more cpd(s). selected from (A), (B) and (C) as ingredient is new. (A) is a pyrimidine (IIa) and/or purine (IIb), base; (B) is nucleoside(s) (III) having (IIa) or (IIb) as base(s); and, (C) are nucleotide(s) (IV) having (IIa) or (IIb) as base(s). Pref. (IIa) is thymine, uracil, or cytosine; (IIb) is adenine, guanine or hypoxanthine; (III) is adenosine, guanosine, cytidine, uridine, thymidine or inosine; and (IV) is adenylic acid, guanylic acid, cytidylic acid, uridylic acid, thymidylic acid or inosinic acid.

Ingredient(s) are blended with conventional additive(s) such as lactose, corn starch, crystalline cellulose, carboxymethylcellulose, methyl p-oxybenzoate etc. to obtain prepn.; or (IIa), (IIb), (III), (IV) may be used as a food additive.


USE/ADVANTAGE - (I) is useful in hypercholesterolaemia to treat and/or prevent arteriosclerosis. (IIa), (IIb), (III) and (IV) are well known and stable cpds., readily available and easily formulated.




United States Patent and Trademark Office

Home | Site Index | Search | Guides | Contacts | eBusiness | eBiz alerts | News | Help

PATENT APPLICATION INFORMATION RETRIEVAL



Other Links



| Image File Wrapper for Application No.: 09/920,394 | | | | NEW Changes to IFW Download | | |
|--|---|-------------------|------------|-----------------------------|--------------------------|----------|
| Mail Room Date | Document Description | Document Category | Page Count | All | None | Download |
| 07/12/2004 | Examiner Interview Summary Record (PTOL - 413) | PROSECUTION | 2 | | <input type="checkbox"/> | |
| 06/21/2004 | Notice of Appeal Filed | PROSECUTION | 3 | | <input type="checkbox"/> | |
| 03/22/2004 | Final Rejection | PROSECUTION | 13 | | <input type="checkbox"/> | |
| 03/22/2004 | Claims recorded on File Wrapper | PROSECUTION | 1 | | <input type="checkbox"/> | |
| 03/22/2004 | Oath or Declaration filed | PROSECUTION | 9 | | <input type="checkbox"/> | |
| 03/22/2004 | Search info on File Wrapper | PROSECUTION | 1 | | <input type="checkbox"/> | |
| 01/21/2004 | Fee Worksheet (PTO-875) | PROSECUTION | 1 | | <input type="checkbox"/> | |
| 01/07/2004 | Claim | PROSECUTION | 3 | | <input type="checkbox"/> | |
| 01/07/2004 | Applicant Arguments or Remarks Made in an Amendment | PROSECUTION | 9 | | <input type="checkbox"/> | |
| 01/07/2004 | Affidavit(s) (Rule 131 or 132) or Exhibit(s) Received | PROSECUTION | 9 | | <input type="checkbox"/> | |
| 01/07/2004 | Extension of time from Applicant - filed as separate letter | PROSECUTION | 1 | | <input type="checkbox"/> | |
| 01/07/2004 | Transmittal to TC | PROSECUTION | 2 | | <input type="checkbox"/> | |
| 01/07/2004 | Amendment | PROSECUTION | 1 | | <input type="checkbox"/> | |
| 07/16/2003 | Requirement for Restriction/Election | PROSECUTION | 11 | | <input type="checkbox"/> | |
| 05/13/2003 | Change of Address | PROSECUTION | 1 | | <input type="checkbox"/> | |

| | | | | |
|------------|---|-------------|----|--------------------------|
| 05/06/2003 | Request for Continued Examination (RCE) | PROSECUTION | 1 | <input type="checkbox"/> |
| 05/06/2003 | Information Disclosure Statement | PROSECUTION | 3 | <input type="checkbox"/> |
| 05/06/2003 | Extension of time from Applicant - filed as separate letter | PROSECUTION | 2 | <input type="checkbox"/> |
| 05/06/2003 | Applicant Arguments or Remarks Made in an Amendment | PROSECUTION | 4 | <input type="checkbox"/> |
| 05/06/2003 | Claim | PROSECUTION | 3 | <input type="checkbox"/> |
| 05/06/2003 | Transmittal to TC | PROSECUTION | 1 | <input type="checkbox"/> |
| 05/06/2003 | Amendment Submitted/Entered with Filing of CPA/RCE | PROSECUTION | 1 | <input type="checkbox"/> |
| 04/24/2003 | Miscellaneous Action with SSP | PROSECUTION | 2 | <input type="checkbox"/> |
| 04/14/2003 | Change in Power of Attorney (May include Associate POA) | PROSECUTION | 4 | <input type="checkbox"/> |
| 03/03/2003 | Information Disclosure Statement | PROSECUTION | 6 | <input type="checkbox"/> |
| 12/04/2002 | Final Rejection | PROSECUTION | 7 | <input type="checkbox"/> |
| 09/16/2002 | Claim | PROSECUTION | 1 | <input type="checkbox"/> |
| 09/16/2002 | Applicant Arguments or Remarks Made in an Amendment | PROSECUTION | 10 | <input type="checkbox"/> |
| 09/16/2002 | Transmittal to TC | PROSECUTION | 2 | <input type="checkbox"/> |
| 09/16/2002 | Amendment | PROSECUTION | 1 | <input type="checkbox"/> |
| 06/18/2002 | Non-Final Rejection | PROSECUTION | 12 | <input type="checkbox"/> |
| 06/05/2002 | Applicant Arguments or Remarks Made in an Amendment | PROSECUTION | 3 | <input type="checkbox"/> |
| 06/05/2002 | Transmittal to TC | PROSECUTION | 2 | <input type="checkbox"/> |
| 06/05/2002 | Preliminary Amendment | PROSECUTION | 1 | <input type="checkbox"/> |
| 01/28/2002 | Pre-Exam Formalities Notice | PROSECUTION | 3 | <input type="checkbox"/> |
| 01/28/2002 | Oath or Declaration filed | PROSECUTION | 8 | <input type="checkbox"/> |
| 01/28/2002 | Information Disclosure Statement | PROSECUTION | 3 | <input type="checkbox"/> |
| 10/18/2001 | Miscellaneous Action with SSP | PROSECUTION | 1 | <input type="checkbox"/> |

| 10/09/2001 | CRF Sequence Listing Filed | PROSECUTION | 10 | <input type="checkbox"/> |
|------------|---------------------------------------|-------------|-----|--------------------------|
| 08/01/2001 | Claims recorded on File Wrapper | PROSECUTION | 1 | <input type="checkbox"/> |
| 08/01/2001 | Transmittal of New Application | PROSECUTION | 5 | <input type="checkbox"/> |
| 08/01/2001 | Specification | PROSECUTION | 91 | <input type="checkbox"/> |
| 08/01/2001 | CRF Sequence Listing Filed | PROSECUTION | 2 | <input type="checkbox"/> |
| 08/01/2001 | Sequence List | PROSECUTION | 18 | <input type="checkbox"/> |
| 08/01/2001 | Claims Worksheet (PTO-2022) | PROSECUTION | 1 | <input type="checkbox"/> |
| 08/01/2001 | Issue Information on File Wrapper | PROSECUTION | 1 | <input type="checkbox"/> |
| 08/01/2001 | Search info on File Wrapper | PROSECUTION | 1 | <input type="checkbox"/> |
| 08/01/2001 | Fee Worksheet (PTO-875) | PROSECUTION | 1 | <input type="checkbox"/> |
| 08/01/2001 | Fee Worksheet (PTO-875) | PROSECUTION | 1 | <input type="checkbox"/> |
| 08/01/2001 | Oath or Declaration filed | PROSECUTION | 4 | <input type="checkbox"/> |
| 08/01/2001 | Abstract | PROSECUTION | 1 | <input type="checkbox"/> |
| 08/01/2001 | Claim | PROSECUTION | 3 | <input type="checkbox"/> |
| 03/22/2004 | List of references cited by Examiner | PRIOR ART | 1 | <input type="checkbox"/> |
| 02/04/2004 | Examiner Search Notes | PRIOR ART | 425 | <input type="checkbox"/> |
| 02/04/2004 | Examiner Search Notes | PRIOR ART | 584 | <input type="checkbox"/> |
| 07/16/2003 | NPL Documents | PRIOR ART | 7 | <input type="checkbox"/> |
| 07/16/2003 | List of references cited by Examiner | PRIOR ART | 1 | <input type="checkbox"/> |
| 07/16/2003 | List of References cited by Applicant | PRIOR ART | 2 | <input type="checkbox"/> |
| 05/21/2003 | Examiner Search Notes | PRIOR ART | 50 | <input type="checkbox"/> |
| 05/06/2003 | Foreign Reference | PRIOR ART | 119 | <input type="checkbox"/> |
| 05/06/2003 | Foreign Reference | PRIOR ART | 58 | <input type="checkbox"/> |
| 05/06/2003 | NPL Documents | PRIOR ART | 18 | <input type="checkbox"/> |
| 05/06/2003 | NPL Documents | PRIOR ART | 6 | <input type="checkbox"/> |



| | | | | |
|------------|---------------------------------------|-----------|----|--------------------------|
| 05/06/2003 | NPL Documents | PRIOR ART | 7 | <input type="checkbox"/> |
| 05/06/2003 | NPL Documents | PRIOR ART | 8 | <input type="checkbox"/> |
| 05/06/2003 | Foreign Reference | PRIOR ART | 54 | <input type="checkbox"/> |
| 05/06/2003 | Foreign Reference | PRIOR ART | 5 | <input type="checkbox"/> |
| 03/03/2003 | NPL Documents | PRIOR ART | 7 | <input type="checkbox"/> |
| 12/04/2002 | List of references cited by Examiner | PRIOR ART | 1 | <input type="checkbox"/> |
| 06/18/2002 | NPL Documents | PRIOR ART | 9 | <input type="checkbox"/> |
| 06/18/2002 | NPL Documents | PRIOR ART | 9 | <input type="checkbox"/> |
| 06/18/2002 | NPL Documents | PRIOR ART | 13 | <input type="checkbox"/> |
| 06/18/2002 | NPL Documents | PRIOR ART | 6 | <input type="checkbox"/> |
| 06/18/2002 | NPL Documents | PRIOR ART | 4 | <input type="checkbox"/> |
| 06/18/2002 | List of references cited by Examiner | PRIOR ART | 2 | <input type="checkbox"/> |
| 06/18/2002 | List of References cited by Applicant | PRIOR ART | 6 | <input type="checkbox"/> |
| 06/14/2002 | Examiner Search Notes | PRIOR ART | 7 | <input type="checkbox"/> |
| 06/06/2002 | Examiner Search Notes | PRIOR ART | 82 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 10 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 40 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 8 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 8 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 13 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 7 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 17 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 14 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 10 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 7 | <input type="checkbox"/> |

| | | | | |
|------------|---------------|-----------|----|--------------------------|
| 01/28/2002 | NPL Documents | PRIOR ART | 7 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 10 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 36 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 13 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 9 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 27 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 11 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 14 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 22 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 17 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 8 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 5 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 2 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 8 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 8 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 7 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 6 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 10 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 7 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 14 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 9 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 11 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 13 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 10 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 10 | <input type="checkbox"/> |

| | | | | |
|------------|--------------------------------|-----------|----|--------------------------|
| 01/28/2002 | NPL Documents | PRIOR ART | 11 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 5 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 11 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 14 | <input type="checkbox"/> |
| 01/28/2002 | NPL Documents | PRIOR ART | 9 | <input type="checkbox"/> |
| 08/01/2001 | Oath or Declaration filed | AS FILED | 4 | <input type="checkbox"/> |
| 08/01/2001 | Abstract | AS FILED | 1 | <input type="checkbox"/> |
| 08/01/2001 | Claim | AS FILED | 3 | <input type="checkbox"/> |
| 08/01/2001 | Specification | AS FILED | 91 | <input type="checkbox"/> |
| 08/01/2001 | Transmittal of New Application | AS FILED | 7 | <input type="checkbox"/> |
| 08/01/2001 | Sequence List | AS FILED | 18 | <input type="checkbox"/> |

Sorted By : Document Category

[| HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.